Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case

Leukemia Research

Volumn 29, Issue 2, 2005, Pages 131-134

  Butterfield, Joseph H ^a   Tefferi, Ayalew ^a   Kozuh, Gerald F ^b  

^a MAYO CLINIC   (United States)

^b Oncology Joint Practice   (United States)

Author keywords

c kit mutation; Interferon alfa; Prostaglandin F2 ; Systemic mastocytosis therapy; Tryptase

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CALCITONIN; GLUCOSAMINE; LEVOTHYROXINE; MULTIVITAMIN; N METHYLHISTAMINE; PARACETAMOL; PREDNISONE; PROSTAGLANDIN F2 ALPHA; TRYPTASE;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; BODY WEIGHT; BONE MARROW; BONE MARROW BIOPSY; CALCITONIN BLOOD LEVEL; CASE REPORT; CELL INFILTRATION; DEPRESSION; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME BLOOD LEVEL; FOLLOW UP; HEMOCONCENTRATION; HEPATOSPLENOMEGALY; HUMAN; HYPOTHYROIDISM; INJECTION; LEUKOCYTOSIS; MALE; MAST CELL; MEDIATOR; MUTATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; SYSTEMIC MASTOCYTOSIS; URINARY EXCRETION; URTICARIA PIGMENTOSA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MASTOCYTOSIS, SYSTEMIC; TREATMENT OUTCOME;

EID: 10644277956     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.05.003     Document Type: Article

References (29)

1. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 108:1996;385-397
2. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25:2001;603-625
3. Keyzer J.J., de Monchy J.G., van Doormaal J.J., van Voorst Vader P.C. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N. Engl. J. Med. 309:1983;1603-1605
4. Roberts L.J. II, Sweetman B.J., Lewis R.A., Austen K.F., Oates J.A. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N. Engl. J. Med. 303:1980;1400-1404
5. Wodnar-Filipowicz A., Heusser C.H., Moroni C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature. 339:1989;150-152
6. Moller A., Lippert U., Lessmann D., Kolde G., Hamann K., Welker P., et al. Human mast cells produce IL-8. J. Immunol. 151:1993;3261-3266
7. Grabbe J., Welker P., Moller A., Dippel E., Ashman L.K., Czarnetzki B.M. Comparative cytokine release from human monocytes, monocyte-derived immature mast cells, and a human mast cell line (HMC-1). J. Invest. Dermatol. 103:1994;504-508
8. Tunon de Lara J.M., Okayama Y., McEuen A.R., Heusser C.H., Church M.K., Walls A.F. Release and inactivation of interleukin-4 by mast cells. Ann. N.Y. Acad. Sci. 725:1994;50-58
9. Bradding P., Holgate S.T. The mast cell as a source of cytokines in asthma. Ann. N.Y. Acad. Sci. 796:1996;272-281
10. Toru H., Pawankar R., Ra C., Yata J., Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J. Allergy Clin. Immunol. 102:1998;491-502
11. Hirschowitz B.I., Groarke J.F. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann. Intern. Med. 90:1979;769-771
12. Soter N.A., Austen K.F., Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301:1979;465-469
13. Lewis R.A. Mastocytosis. J. Allergy Clin. Immunol. 74:1984;755-765
14. Butterfield J.H., Kao P.C., Klee G.C., Yocum M.W. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin. Proc. 70:1995;481-487
15. Granerus G., Lonnqvist B., Roupe G. Histamine metabolism in mastocytosis patients treated with interferon α-2b. Inflamm. Res. 45(Suppl. 1):1996;S41-S43
16. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., Metcalfe D.D. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma. 22:1996;501-508
17. Casassus P., Caillat-Vigneron N., Martin A., Simon J., Gallais V., Beaudry P., et al. Treatment of adult systemic mastocytosis with inferon-α: results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 119:2002;1090-1097
18. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., Wolthers B.G., Kluin P.M., Kroon H.M., et al. Response to inferferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326:1992;619-623
19. Harrison B.D., Ashford R.A., Hatton C.S. Systemic mastocytosis - a case treated with interferon α and radiotherapy. Clin. Lab. Haematol. 16:1994;291-294
20. Petit A., Pulik M., Gaulier A., Lionnet F., Mahe A., Sigal M. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy. J. Am. Acad. Dermatol. 32:1995;850-853
21. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 138:1998;489-495
22. Pulik M., Lionnet F., Petit A., Genet P., Gaulier A. Long-term response to interferon-α in a patient with systemic mastocytosis and chronic myelomonocytic leukemia (letter to the editor). Am. J. Hematol. 47:1994;66
23. Kolde G., Sunderkotter C., Luger T.A. Treatment of urticaria pigmentosa using interferon alpha. Br. J. Dermatol. 133:1995;91-94
24. Delaporte E., Piérard E., Wolthers B.G., Desreumaux P., Janin A., Cortot A., et al. Interferon-α in combination with corticosteroids improves systemic mast cell disease. Br. J. Dermatol. 132:1995;479-482
25. Weide R., Ehlenz K., Lorenz W., Walthers E., Klausmann M., Pflüger K.-H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 72:1996;41-43
26. Czarnetzki B.M., Algermissen B., Jeep S., Haas N., Nurnberg W., Muller K., et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J. Am. Acad. Dermatol. 30:1994;500-501
27. Pardini S., Bosincu L., Bonfigli S., Dore F., Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 85:1991;220
28. Irani A.A., Nilsson G., Ashman L.K., Schwartz L.B. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology. 84:1995;72-78
29. Finotto S., Mekori Y.A., Metcalfe D.D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 99:1997;1721-1728